These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 18434717)

  • 41. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.
    Ginès P; Guevara M
    Hepatology; 2008 Sep; 48(3):1002-10. PubMed ID: 18671303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment options for hyponatremia in heart failure.
    Goldsmith SR
    Congest Heart Fail; 2010 Jul; 16 Suppl 1():S15-8. PubMed ID: 20653706
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
    Soupart A; Gross P; Legros JJ; Alföldi S; Annane D; Heshmati HM; Decaux G
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1154-60. PubMed ID: 17699341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of vaptans in the management of hyponatremia.
    Lehrich RW; Ortiz-Melo DI; Patel MB; Greenberg A
    Am J Kidney Dis; 2013 Aug; 62(2):364-76. PubMed ID: 23725974
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
    Farmakis D; Filippatos G; Kremastinos DT; Gheorghiade M
    Curr Heart Fail Rep; 2008 Jun; 5(2):91-6. PubMed ID: 18765079
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hyponatremia in heart failure.
    Chatterjee K
    J Intensive Care Med; 2009; 24(6):347-51. PubMed ID: 19850560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of hyponatremia.
    Goh KP
    Am Fam Physician; 2004 May; 69(10):2387-94. PubMed ID: 15168958
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current therapeutic options for hyponatremia: indications, limitations, and confounding variables.
    Human T
    Pharmacotherapy; 2011 May; 31(5 Suppl):18S-24S. PubMed ID: 21923422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Consequences of inadequate management of hyponatremia.
    Adrogué HJ
    Am J Nephrol; 2005; 25(3):240-9. PubMed ID: 15914973
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The potential role for lixivaptan in heart failure and in hyponatremia.
    Zmily HD; Khan NS; Daifallah S; Ghali JK
    Expert Opin Investig Drugs; 2011 Jun; 20(6):831-48. PubMed ID: 21548825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current Management of Hyponatremia in Acute Heart Failure: A Report From the Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry).
    Dunlap ME; Hauptman PJ; Amin AN; Chase SL; Chiodo JA; Chiong JR; Dasta JF
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28775063
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vasopressin receptor antagonists: potential indications and clinical results.
    Arai Y; Fujimori A; Sudoh K; Sasamata M
    Curr Opin Pharmacol; 2007 Apr; 7(2):124-9. PubMed ID: 17292670
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Electrolyte abnormalities and metabolic acidosis in two Duchenne muscular dystrophy patients with advanced congestive heart failure].
    Matsumura T; Saito T; Miyai I; Nozaki S; Kang J
    Rinsho Shinkeigaku; 2000 May; 40(5):439-45. PubMed ID: 11002725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cerebral correlates of hyponatremia.
    Nathan BR
    Neurocrit Care; 2007; 6(1):72-8. PubMed ID: 17356196
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hyponatremia: clinical diagnosis and management.
    Lien YH; Shapiro JI
    Am J Med; 2007 Aug; 120(8):653-8. PubMed ID: 17679119
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of vasopressin receptor antagonists in hyponatremia.
    Khanna A; Menon MC
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
    Izumi Y; Miura K; Iwao H
    J Pharmacol Sci; 2014; 124(1):1-6. PubMed ID: 24401675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vasopressin and vasopressin receptor antagonists in heart failure.
    Oghlakian G; Klapholz M
    Cardiol Rev; 2009; 17(1):10-5. PubMed ID: 19092365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
    Ali F; Raufi MA; Washington B; Ghali JK
    Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.